Core Viewpoint - Lumexa Imaging, a provider of outpatient imaging diagnostic services, has successfully launched on the US stock market with an opening price of $18.8, slightly above its IPO price of $18.5 [1] Company Overview - Lumexa Imaging is headquartered in North Carolina and operates 184 diagnostic centers across 13 states in the US [1] - The company was co-founded in 2018 by Charlotte Radiology and investment firm Welsh, Carson, Anderson & Stowe, starting with only 20 centers [1] - Lumexa Imaging has expanded through 20 acquisitions and the establishment of 41 new locations [1] Services Offered - The company provides a range of advanced and routine imaging services, including MRI, CT, PET, X-ray, ultrasound, and mammography [1] Network and Partnerships - Lumexa Imaging has developed a diversified referral network, collaborating with over 29,000 medical institutions and approximately 100,000 physicians [1] Financial Performance - The company reported projected sales of $1 billion for the 12 months ending September 30, 2025 [1]

Group 1 - Lumexa Imaging Holdings (LMRI.US) has submitted an IPO application to the SEC, aiming to raise up to $200 million [1][2] - The company operates 184 diagnostic imaging centers across 13 states, providing advanced and routine imaging services including MRI, CT, PET, X-ray, ultrasound, and mammography [1] - Lumexa Imaging was founded in 2018 by Charlotte Radiology and Welsh, Carson, Anderson & Stowe, starting with 20 centers and expanding through 20 acquisitions and the opening of 41 new locations [1] Group 2 - The company achieved revenue of $1 billion for the 12 months ending September 30, 2025, and plans to list on the NASDAQ under the ticker symbol LMRI [2] - The IPO's joint bookrunners include Barclays, JPMorgan, Jefferies, Deutsche Bank, Wells Fargo Securities, Leerink Partners, William Blair, Capital One Securities, Fifth Third Securities, Raymond James, and PNC Capital Markets [2] - The pricing terms for the offering have not yet been disclosed [2]